MET (MetLife) Research & Development: $0 Mil (TTM As of Mar. 2026)


MET MetLife Inc MET
76 GF Score
Price $84.60
GF Value $89.60
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is MetLife Research & Development?

MetLife MET -3.90% 76 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates MET with a GF Score™ of 76/100 and a GF Value™ of $89.60 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MetLife's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

MetLife  (NYSE:MET) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MetLife Research & Development Related Terms

MetLife Research & Development Historical Data

* Premium members only.

The historical data trend for MetLife's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetLife Research & Development Chart

MetLife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetLife Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MET
76GF Score
MetLife Inc MET
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MetLife Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
MetLife (MET) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MetLife and its competitors.
Is MetLife's Research & Development too high?
MetLife's current Research & Development is $0 Mil. Overall, MetLife has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MetLife's Research & Development compare to AFL and PRU?
MetLife's Research & Development of $0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MetLife and its competitors. MetLife's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetLife stock overvalued right now?
Based on GuruFocus' analysis, MetLife (MET) is currently considered Fairly Valued. The stock's GF Value™ is $89.60, compared to a current price of $84.60 — trading 5.6% below its estimated fair value. The current Research & Development is $0 Mil. MetLife's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MetLife (MET), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MetLife (MET) Overvalued in 2026?

Based on GuruFocus' analysis, MetLife stock appears to be undervalued. The current stock price of $84.60 is trading 5.6% below its estimated GF Value™ of $89.60. GuruFocus considers MetLife to be Fairly Valued.

Key valuation signals for MET:

  • Research & Development: $0 Mil
  • GF Value™: $89.60 vs. price of $84.60 (5.6% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the MET stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MetLife Business Description

Address 200 Park Avenue, New York, NY, USA, 10166-0188
MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products. It is organized into six segments: Group Benefits, Retirement and Income Solutions, Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Holdings (products in run-off). Group Benefits and RIS are US-based, contributing to around 48% of the firm's 2024 adjusted earnings. The Asia segment contributes around 25% of earnings, mainly tied to Japan. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of 2024 earnings. The EMEA and MetLife Holdings segments contributed around 4% and 10% of 2024 earnings, respectively.
76GF Score

Get the complete analysis for MET

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$84.60
Price
$89.60
GF Value